Urology News and Research

Latest Urology News and Research

Surgery could boost chemotherapy outcomes in canine TCC

Dogs that undergo curative surgery for transitional cell carcinoma before initiating a combination of doxorubicin and piroxicam therapy have significantly longer median overall survival than their counterparts not pretreated surgically, report researchers.

6 Feb 2013

Previously poorly investigated signalling pathway crucial for proliferation of prostate cancer cells

A previously poorly investigated signalling pathway is crucial for the growth and proliferation of prostate cancer cells. An international research team discovered this when studying the enzyme "soluble adenylyl cyclase" that produces the second messenger molecule cAMP.

5 Feb 2013

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

Delayed hematuria common after prostate brachytherapy

A significant proportion of patients with prostate cancer who are treated with brachytherapy develop gross hematuria years later, report researchers.

4 Feb 2013

Risk factors identified for renal abnormality in vesicoureteral reflux

Researchers have identified the main risk factors for renal functional abnormalities in children with high-grade vesicoureteral reflux.

4 Feb 2013

Glycemic control low priority in diabetes CVD prevention

Maintaining glycemic control does not reduce the likelihood for cardiovascular disease leading to hospitalization in people with Type 2 diabetes, report US researchers.

4 Feb 2013

Weill Cornell and NewYork-Presbyterian create pioneering Institute for Precision Medicine

Recognizing that medicine is not "one size fits all," Weill Cornell Medical College and NewYork-Presbyterian Hospital have created the pioneering Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. This new, cutting-edge translational medicine research hub will explore the new frontier of precision medicine, offering optimal targeted, individualized treatment based on each patient's genetic profile.

1 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Potty training right from the birth can eliminate need for diapers

Western babies are potty trained later these days and need diapers until an average of three years of age. But even infants can be potty trained. A study by researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, followed 47 infants and their mothers in Vietnam - where potty training starts at birth and the need for diapers is usually eliminated by nine months of age.

31 Jan 2013

Microscopic hematuria poor indicator for renal, bladder malignancy

The presence of microscopic levels of blood in the urine is unreliable as an indicator for renal or bladder cancer, report researchers.

30 Jan 2013

Pelvic floor exercises after RP ‘sufficient’

Performing pelvic floor muscle training both before and after radical prostatectomy is no more effective at reducing postoperative urinary incontinence than performing the exercises after surgery, report researchers.

30 Jan 2013

Prediagnostic androgen level not linked to prostate cancer outcome

Low prediagnostic levels of circulating sex hormones are not associated with more aggressive disease in patients with prostate cancer, say US researchers.

28 Jan 2013

Merck receives FDA approval for Oxytrol to treat overactive bladder in women

The U.S. Food and Drug Administration today approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older.

28 Jan 2013

Simple urine test picks up mesalamine non-adherence

A readily available urine test could identify ulcerative colitis patients who are non-adherent to their mesalamine therapy, research shows.

25 Jan 2013

Researchers identify cancer-associated mutations

Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously found.

25 Jan 2013

Findings could help explain prevalence of urinary tract infections in post-menopausal women

Researchers from Washington University School of Medicine, St. Louis, show that reservoirs of uropathogenic E. coli within the bladder exist in higher numbers post-menopause than pre-menopause in a mouse model, a finding that could help explain the greater prevalence of urinary tract infections in post-menopausal women.

25 Jan 2013

Sacral nerve stimulation helps manage children with chronic incontinence

Incontinence is typically a condition associated with adults; however, many children also struggle with incontinence - bladder, bowel or both. In order to help these children, doctors at Nationwide Children's Hospital have turned to a device, typically used in adult patients, to help manage children with chronic incontinence.

24 Jan 2013

Boosting estrogen levels may help reduce urinary infections in menopausal women

Estrogen levels drop dramatically in menopause, a time when the risk of urinary tract infections increases significantly.

24 Jan 2013

Actavis seeks FDA approval to market generic Opana ER

Watson Pharmaceuticals, Inc. today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets.

23 Jan 2013

Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate.

22 Jan 2013